Annals of Hematology

, Volume 92, Issue 8, pp 1033–1040 | Cite as

Rituximab, bendamustine, and lenalidomide in patients with aggressive B cell lymphoma not eligible for high-dose chemotherapy or anthracycline-based therapy: phase I results of the SAKK 38/08 trial

  • F. Hitz
  • N. Fischer
  • Th. Pabst
  • C. Caspar
  • G. Berthod
  • K. Eckhardt
  • S. Berardi Vilei
  • E. Zucca
  • U. Mey
  • On behalf of Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
Original Article

Abstract

This phase I trial was designed to develop a new effective and well-tolerated regimen for patients with aggressive B cell lymphoma not eligible for front-line anthracycline-based chemotherapy or aggressive second-line treatment strategies. The combination of rituximab (375 mg/m2 on day 1), bendamustine (70 mg/m2 on days 1 and 2), and lenalidomide was tested with a dose escalation of lenalidomide at three dose levels (10, 15, or 20 mg/day) using a 3 + 3 design. Courses were repeated every 4 weeks. The recommended dose was defined as one level below the dose level identifying ≥2/6 patients with a dose-limiting toxicity (DLT) during the first cycle. Thirteen patients were eligible for analysis. Median age was 77 years. WHO performance status was 0 or 1 in 12 patients. The Charlson Comorbidity Index showed relevant comorbidities in all patients. Two DLTs occurred at the second dose level (15 mg/day) within the first cycle: one patient had prolonged grade 3 neutropenia, and one patient experienced grade 4 cardiac adverse event (myocardial infarction). Additional grade 3 and 4 toxicities were as follows: neutropenia (31 %), thrombocytopenia (23 %), cardiac toxicity (31 %), fatigue (15 %), and rash (15 %). The dose of lenalidomide of 10 mg/day was recommended for a subsequent phase II in combination with rituximab 375 mg/m2 on day 1 and bendamustine 70 mg/m2 on days 1 and 2.

Keywords

Aggressive B cell lymphoma Relapse Elderly Rituximab Bendamustine Lenalidomide 

Notes

Acknowledgments

This trial was sponsored by the Swiss Group for Clinical Cancer Research (SAKK). SAKK was responsible for the study design, study conduct, analysis, and manuscript writing. Roche Pharma (Schweiz) AG, Mundipharma Medical Company (Schweiz), and Celgene GmbH supported the study in part financially, supplied the study drug, and offered comments in the process of manuscript writing. This trial was also supported by the Swiss State Secretariat for Education and Research (SER).

Conflict of interest

EZ has participation in the Roche and Celgene advisory boards. All other authors declare no conflict of interest.

References

  1. 1.
    Weisenburger DD (1994) Epidemiology of non-Hodgkin's lymphoma: recent findings regarding an emerging epidemic. Ann Oncol 5(Suppl 1):19–24PubMedCrossRefGoogle Scholar
  2. 2.
    Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS (2006) Lymphoma incidence patterns by WHO subtype in the United States, 1992–2001. Blood 107:265–276PubMedCrossRefGoogle Scholar
  3. 3.
    Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Fermé C, Christian B, Lepage E, Tilly H, Morschhauser F, Gaulard P, Salles G, Bosly A, Gisselbrecht C, Reyes F, Coiffier B (2005) Long-term results of the R-CHOP Study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol 23:4117–4126PubMedCrossRefGoogle Scholar
  4. 4.
    Gisselbrecht C, Glass B, Mounier N, Gill DS, Linch DC, Trneny M, Bosly A, Ketterer N, Shpilberg O, Hagberg H, Ma D, Brière J, Moskowitz CH, Schmitz N (2010) Salvage regimens with autologous transplantation for relapsed large B cell lymphoma in the rituximab era. J Clin Oncol 28:4184–4190PubMedCrossRefGoogle Scholar
  5. 5.
    van Spronsen DJ, Janssen-Heijnen MLG, Breed WPM, Coebergh JWW (1999) Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993–1996. Ann Hematol 78:315–319PubMedCrossRefGoogle Scholar
  6. 6.
    Thieblemont C, Grossoeuvre A, Houot R, Broussais-Guillaumont F, Salles G, Traulle C, Espinouse D, Coiffier B (2008) Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 19:774–779PubMedCrossRefGoogle Scholar
  7. 7.
    van de Schans SAM, Wymenga ANM, van Spronsen DJ, Schouten HC, Coebergh JWW, Janssen-Heijnen MLG (2012) Two sides of the medallion: poor treatment tolerance but better survival by standard chemotherapy in elderly patients with advanced-stage diffuse large B-cell lymphoma. Ann Oncol 23:1280–1286PubMedCrossRefGoogle Scholar
  8. 8.
    Friedberg JW, Cohen P, Chen L, Robinson KS, Forero-Torres A, La Casce AS, Fayad LE, Bessudo A, Camacho ES, Williams ME, van der Jagt RH, Oliver JW, Cheson BD (2008) Bendamustine in patients with rituximab-refractory indolent and transformed non-Hodgkin's lymphoma: results from a phase II multicenter, single-agent study. J Clin Oncol 10:204–10CrossRefGoogle Scholar
  9. 9.
    Kahl BS, Bartelett NL, Leonard JP, Chen L, Ganjoo K, Williams ME, Czuczman MS, Robinson KS, Joyce R, van der Jagt RH, Cheson BD (2010) Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma. Cancer 116:106–114PubMedGoogle Scholar
  10. 10.
    Rigacci L, Puccini B, Cortelazzo S, Gaidano G, Piccin A, D'Arco A, Freilone R, Storti S, Orciuolo E, Zinzani PL, Zaja F, Bongarzoni V, Balzarotti M, Rota-Scalabrini D, Patti C, Gobbi M, Carpaneto A, Liberati AM, Bosi A, Iannitto E (2012) Bendamustine with or without rituximab for the treatment of heavily pretreated non-Hodgkin's lymphoma patients. Ann Hematol 91:1013–1022PubMedCrossRefGoogle Scholar
  11. 11.
    Rummel M, Niederle N, Maschmeyer G, et al (2012) Bendamustine plus rituximab (B-R) versus CHOP plus rituximab (CHOP-R) as a first-line treatment in patients with indolent and mantle cell lymphomas (MCL): updated results from the StiL NHL1 study. J Clin Oncol 30: Abstract 3Google Scholar
  12. 12.
    Ogura M, Ando K, Taniwaki M, Watanabe T, Uchida T, Ohmachi K, Matsumoto Y, Tobinai K (2011) Feasibility and pharmacokinetic study of bendamustine hydrochloride in combination with rituximab in relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Cancer Sci 102(9):1687–92PubMedCrossRefGoogle Scholar
  13. 13.
    Walter E, Schmitt T, Dietrich S, Ho A, Witzens-Harig M (2012) Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. Leuk Lymphoma 53:2290–2PubMedCrossRefGoogle Scholar
  14. 14.
    Horn J, Kleber M, Hieke S, Schmitt-Gräff A, Wäsch R, Engelhardt M (2012) Treatment option of bendamustine in combination with rituximab in elderly and frail patients with aggressive B-non-Hodgkin lymphoma: rational, efficacy, and tolerance. Ann Hematol 91:1579–1586PubMedCrossRefGoogle Scholar
  15. 15.
    Weidmann E, Neumann A, Fauth F, Atmaca A, Al-Batran SE, Pauligk C, Jäger E (2011) Phase II study of bendamustine in combination with rituximab as first-line treatment in patients 80 years or older with aggressive B-cell lymphomas. Ann Oncol 22:1839–44PubMedCrossRefGoogle Scholar
  16. 16.
    Witzig TE, Vose JM, Zinzani PL, Reeder CB, Buckstein R, Polikoff JA, Bouabdallah R, Haioun C, Tilly Guo HP, Pietronigro D, Ervin-Haynes AL, Czuczman MS (2011) An international phase II trial of single-agent lenalidomide for relapsed or refractory aggressive B-cell non-Hodgkin's lymphoma. Ann Oncol 22:1622–1627PubMedCrossRefGoogle Scholar
  17. 17.
    Czuczman MS, Vose JM, Witzig TE, Zinzani PL, Buckstein R, Polikoff J, Li J, Pietronigro D, Ervin-Haynes A, Reeder CB (2011) The differential effect of lenalidomide monotherapy in patients with relapsed or refractory transformed non-Hodgkin lymphoma of distinct histological origin. Br J Haematol 154:477–481PubMedCrossRefGoogle Scholar
  18. 18.
    Zinzani PL, Pellegrini C, Gandolfi L, Stefoni V, Quirini F, Derenzini E, Broccoli A, Argnani L, Pileri S, Baccarani M (2011) Combination of lenalidomide and rituximab in elderly patients with relapsed or refractory diffuse large B-cell lymphoma: a phase 2 trial. Clin Lymphoma Myeloma Leuk 11:462–6PubMedCrossRefGoogle Scholar
  19. 19.
    Balducci L, Extermann M (2000) Management of the frail person with advanced cancer. Crit Rev Oncol Hematol 33(2):143–8PubMedCrossRefGoogle Scholar
  20. 20.
    WHO (2008) WHO classification of tumours of haematopoetic and lymphoid tissue, 4th edn. WHO, GenevaGoogle Scholar
  21. 21.
    Hall WH, Ramachandran R, Narayan S, Jani AB, Vijayakumar S (2004) An electronic application for rapidly calculating Charlson comorbidity score. BMC Cancer 20:4–94Google Scholar
  22. 22.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383PubMedCrossRefGoogle Scholar
  23. 23.
    Kouroukis CT, Browman GP, Esmail R, Meyer RM (2002) Chemotherapy for older patients with newly diagnosed, advanced-stage, aggressive-histology non-Hodgkin lymphoma: a systematic review. Ann Intern Med 136:144–152PubMedCrossRefGoogle Scholar
  24. 24.
    Fowler N, Hagemeister F, McLaughlin P, Kwak L, Romaguera J, Fanale M, Neelapu S, Fayad L, Orlowski L, Wang M, Pro B, Lacerte L, Samaniego F (2011) Lenalidomide plus rituximab is a highly effective and well-tolerated biologic therapy in untreated indolent B cell non-Hodgkin lymphoma. Ann of Oncol 22: Abstract 137Google Scholar
  25. 25.
    Wiernik PH, Lossos IS, Tuscano JM, Justice G, Vose JM, Cole CE, Lam W, McBride K, Wride K, Pietronigro D, Takeshita K, Ervin-Haynes A, Zeldis CB, Habermann TM (2008) Lenalidomide monotherapy in relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 26(30):4952–7PubMedCrossRefGoogle Scholar
  26. 26.
    Lentzsch S, O'Sullivan A, Kennedy RC, Abbas M, Dai L, Pregja SL, Burt S, Boyiadzis M, Roodman GD, Mapara YM, Agha M, Waas J, Shuai Y, Normolle D, Zonder JA (2012) Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study. Blood 119:4608–4613PubMedCrossRefGoogle Scholar
  27. 27.
    Berry JD, Dyer A, Cai X, Garside DB, Ning H, Thomas A, Greenland P, Van Horn L, Tracy RP, Lloyd-Jones DM (2012) Lifetime risks of cardiovasculare disease. N Engl J Med 366:321–9PubMedCrossRefGoogle Scholar
  28. 28.
    Extermann M, Overcash J, Lyman GH, Parr J, Balducci L (1998) Comorbidity and functional status are independent in older cancer patients. J Clin Oncol 16:1582–1587PubMedGoogle Scholar
  29. 29.
    Extermann M (2000) Measuring comorbidity in older cancer patients. Eur J Cancer 36:453–471PubMedCrossRefGoogle Scholar
  30. 30.
    Extermann M (2000) Measurement and impact of comorbidity in older cancer patients. Crit Rev Oncol Hematol 35:181–200PubMedCrossRefGoogle Scholar
  31. 31.
    Mandelblatt JS, Bierman AS, Gold K, Zhang Y, Ng JH, Maserejan N, Hwang Y, Meropol NJ, Hadley J, Silliman RA (2001) Constructs of burden of illness in older patients with breast cancer: a comparison of measurement methods. Health Serv Res 36:1085–1107PubMedGoogle Scholar
  32. 32.
    The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329(14):987–94CrossRefGoogle Scholar

Copyright information

© Springer-Verlag Berlin Heidelberg 2013

Authors and Affiliations

  • F. Hitz
    • 1
  • N. Fischer
    • 2
  • Th. Pabst
    • 3
  • C. Caspar
    • 4
  • G. Berthod
    • 5
  • K. Eckhardt
    • 6
  • S. Berardi Vilei
    • 6
  • E. Zucca
    • 7
  • U. Mey
    • 8
  • On behalf of Swiss Group for Clinical Cancer Research (SAKK), Bern, Switzerland
  1. 1.Kantonsspital St. GallenSt. GallenSwitzerland
  2. 2.KantonsspitalWinterthurSwitzerland
  3. 3.Inselspital BernBernSwitzerland
  4. 4.Kantonsspital BadenBadenSwitzerland
  5. 5.CHUVLausanneSwitzerland
  6. 6.Coordinating CenterSwiss Group for Clinical Cancer Research (SAKK)BernSwitzerland
  7. 7.IOSI (Istituto Oncologico della Svizzera Italiana)BellinzonaSwitzerland
  8. 8.Kantonsspital ChurChurSwitzerland

Personalised recommendations